

Curriculum Vitae

Full Name: James Cheng-Chung Wei

Organization: Chung Shan Medical University Hospital

Position & Title:

Professor, Institute of Medicine

Chief, Division of Allergy, Immunology and Rheumatology

Director, Chinese Medicine Clinical Trial

Educational background & professional experience

After completing his training in rheumatology and clinical immunology at Taichung Veterans General Hospital and Kaohsiung Veterans General Hospital, Dr Wei undertook a clinical fellowship at the Royal National Hospital for Rheumatic Diseases in Bath, UK, under the supervision of Professor Andrei Calin, one of the world's leading experts in ankylosing spondylitis (AS). Dr Wei subsequently pursued a research fellowship at the University of California, Los Angeles (UCLA) Division of Rheumatology in California, USA, under Professor David Yu, investigating the pathogenesis of spondyloarthritis. Dr Wei obtained his PhD based on his study of the epidemiology and pathogenesis of AS.

Dr Wei had published 120 papers in peer-reviewed SCI journals, such as the Lancet, Annals of the Rheumatic Diseases, Arthritis & Rheumatism, Rheumatology, and Plos one. He had conducted over 110 global clinical trials and about 40 investigator-initiated clinical trials. He is currently full membership of the ACR, GRAPPA and ASAS. He is also the scientific advisory board of the APALR, and associate editor of the International Journal of Rheumatic Diseases.

Research Interests

Current major interests are translational research in AS, clinical trials and big data research in rheumatology.

Publications (Max: 5 titles / in sequence of the latest year)

- Tam LS§, **Wei JC§**, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS*. 2018 APLAR axial spondyloarthritis treatment recommendations. *Int J Rheum Dis.* 2019 Mar; 22(3):340-356. (SCI, IF=2.423, RHEUMATOLOGY, Ranking 20/30 = 66.67%). §Co-first authors; *Correspondence.
- van der Heijde D, **Cheng-Chung Wei J**, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying antirheumatic drugs (COAST-V): 16 week results of a phase 3 randomized, double-blind, active-controlled and placebo-controlled trial. *Lancet.* 2018 Oct 22. pii: S0140-6736(18)31946-9. (SCI, IF=53.254, MEDICINE, GENERAL & INTERNAL, Ranking 2/155 =1.29%).
- Baeten D, Østergaard M, **Wei JC***, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. *Ann Rheum Dis.* 2018 Jun 26. pii: annrheumdis-2018-213328. doi: 10.1136/annrheumdis-2018-213328. (SCI, IF=12.350, RHEUMATOLOGY, Ranking 2/30= 6.67%). Correspondence.
- **Wei JC**, Shi LH, Huang JY, Wu XF, Wu R, Chiou JY. Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study. *J Rheumatol.* 2018 Jan 15. 45(3):385-392. (SCI, IF=3.47, RHEUMATOLOGY, Ranking 11/30=36.67%)
- **James Cheng-Chung Wei**. Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs. *Drugs.* 2014 Jul; 4(10):pp1091-1096.(SCI,IF=4.690, TOXICOLOGY, Ranking 10/94=10.64%) (single author)